CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Intellicell Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Intellicell Biosciences Inc
30 E 76th St Fl 6
Phone: (212) 249-3050p:212 249-3050 NEW YORK, NY  10021-2765  United States

This company was Merged or Acquired on 7/14/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
IntelliCell BioSciences, Inc. is a regenerative medicine company. The Company has identified the technologies and laboratory processes to focus on a portfolio of products and services in medicine for the regenerative, preventative and curative elements of age related disease states. The Company's technology process is based upon acquiring the vascular tissue, primarily capillaries that surround fat tissue from the abdomen. Its medical process results in acquiring vascular fraction cells (VFC). The Company has developed a process using ultrasound that results in a cellular composition, known as stromal vascular cells (SVC) or stromal vascular fraction (SVF). VFC include autologous pluripotent adult stem cells, endothelial cells, progenitor cells, fibroblast cells, red blood cells and white blood cells. Its process uses ultrasound to separate the network of capillaries from the adipocytes. The Company focuses on VFC autologous stem cell product candidates.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201412/31/2013YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board MichaelHershman 69 10/30/2013 11/19/2012
President, Chief Executive Officer, Treasurer, Secretary, Director Steven A.Victor 62 10/30/2013 6/3/2011
Interim Chief Financial Officer John M.Huber 8/19/2014 8/19/2014
Interim Chief Operating Officer, Director Leonard L.Mazur 71 2/14/2013 6/3/2011
Director SamKhashman 45 10/18/2013 10/18/2013

Business Names
Business Name
ICBS Research, Inc.
Intellicell Biosciences, Inc.
SVFC
Tech Stem Inc.

General Information
Number of Employees: 6 (As of 12/31/2013)
Outstanding Shares: 7,894,037,082 (As of 11/19/2014)
Shareholders: 137
Stock Exchange: OTC
Federal Tax Id: 911966948
Email Address: info@intellicellbiosciences.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023